Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA GENERIC PROPRANOLOL APPROVALS ARE DE FACTO DENIALS OF AYERST PETITION

Executive Summary

FDA GENERIC PROPRANOLOL APPROVALS ARE DE FACTO DENIALS OF AYERST PETITION to delay ANDA clearance of Inderal solid dose form competitors. Ayerst asked the agency in two July 24 petitions to 1) revise the approval requirements for generic versions of propranolol to include additional testing, and 2) to delay ANDA propranolol approvals until FDA takes action on Ayerst's petition. However, although the agency has not formally responded to Ayerst, the approval on July 31 of two ANDAs for propranolol tablet products (see story, p. 3) effectively nullifies the Ayerst initiative. Ayerst asked that FDA: 1) revise the current FDA guidelines for conducting propranolol HCI bioequivalence studies to add the additional pharmacokinetic and pharmacodynamic testing necessary to adequately evaluate safety and effectiveness; 2) issue a labeling standard that provides adequate information for the use of different brands of propranolol HCI without infringing upon the exclusivity provided the Inderal labeling by the FD&C Act; and 3) establish adequate criteria for assuring the safety of new sources of propranolol HCI." Specifically, Ayerst said that FDA should require "single and multiple dose bioequivalence" and "pharmacodynamic studies" for all dose strengths submitted for review. To "assure the safety of new sources of propranolol HCI," Ayerst said that FDA should also require either "chemical testing that assures the propranolol HCI proposed for use in different brands of propranolol HCI products is the same as that used in Ayerst's Inderal products in regard to impurities present as well as all other relevant characteristics," or "carcinogenicity studies proving the safety of each new source of propranolol HCI." Under the patent restoration/ANDA law, Ayerst said, Inderal labeling includes some indications -- such as for reduction of mortality after heart attack -- that are protected under an exclusive marketing provision. Ayerst said in the petition that FDA should "review this matter and determine whether a labeling standard can be prepared to provide adequate information for use" of generic propranolol products that does not infringe on Ayerst's indications, which are the subject of exclusivity until Sept. 25, 1986.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel